Every 8-K that Surmodics, Inc. (SRDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SRDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRDX filings page.
Surmodics, Inc. (SRDX) completed its previously announced merger with BCE Parent, LLC on November 19, 2025, with Surmodics becoming a wholly owned subsidiary of Parent. Each outstanding share of Surmodics common stock (with certain excluded shares) was converted into the right to receive $43.00 in cash per share, without interest. All outstanding restricted stock units, deferred stock units, restricted shares, and in-the-money stock options were cancelled in exchange for cash based on the same merger price.
In connection with closing, Surmodics repaid in full all obligations under its October 2022 Credit Agreement and terminated a related interest rate swap covering $25.0 million of term loans. The company notified Nasdaq, requested a trading halt, and is being delisted via Form 25, followed by a planned Form 15 to terminate registration and suspend reporting duties. A change in control occurred, the prior board and executive team resigned, and new directors and officers designated by the buyer were installed. The company’s articles and bylaws were also amended and restated at the effective time.
Surmodics (SRDX) reported a key legal development related to its pending acquisition by an affiliate of GTCR LLC. The U.S. District Court for the Northern District of Illinois denied a request by the FTC and certain state regulators for a preliminary injunction that would have prevented the parties from closing the merger.
The company furnished a press release as Exhibit 99.1. This ruling removes a major procedural barrier to closing, though completion of the merger still depends on remaining conditions described elsewhere by the company. The disclosure includes standard forward‑looking statement cautions.
On 8 Aug 2025 Surmodics, Inc. (SRDX) filed a Form 8-K to furnish a press release announcing its financial results for the quarter ended 30 Jun 2025. The press release is attached as Exhibit 99.1, but the filing itself contains no revenue, EPS, balance-sheet or guidance figures. The disclosure falls under Item 2.02 (Results of Operations and Financial Condition) and is expressly marked as “furnished,” not “filed,” which limits Section 18 Exchange Act liability. Aside from the exhibit list and standard representations, the document offers no additional financial data or strategic commentary.